tiprankstipranks
Beximco Pharmaceuticals Limited Sponsored GDR RegS (GB:BXP)
LSE:BXP
UK Market
BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
RESEARCH TOOLSreports

Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP) Financial Statements

Compare
5 Followers

Beximco Pharmaceuticals Limited Sponsored GDR RegS Financial Overview

Beximco Pharmaceuticals Limited Sponsored GDR RegS's market cap is currently $34.26B. The company's EPS TTM is p0.092; its P/E ratio is 4.14; and it has a dividend yield of 5.55%. Beximco Pharmaceuticals Limited Sponsored GDR RegS is scheduled to report earnings on January 29, 2025, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Jun 22Jun 21Jun 20Jun 19
Income Statement
Total Revenue
Gross Profit$ 17.31B$ 41.14B$ 13.92B$ 11.90B$ 10.62B
Operating Income$ 7.17B$ 19.78B$ 6.66B$ 5.51B$ 4.87B
EBITDA$ 9.37B$ 27.12B$ 7.18B$ 5.64B$ 4.93B
Net Income$ 4.61B$ 21.34B$ 5.13B$ 3.51B$ 3.03B
Balance Sheet
Cash & Short-Term Investments$ ―$ ―$ ―$ ―$ ―
Total Assets$ 62.59B$ 179.08B$ 52.25B$ 50.12B$ 49.21B
Total Debt$ 10.07B$ 35.41B$ 7.63B$ 10.50B$ 13.48B
Net Debt$ 9.13B$ 32.97B$ 6.96B$ 9.87B$ 12.55B
Total Liabilities$ 19.25B$ 58.14B$ 14.88B$ 17.32B$ 19.35B
Stockholders' Equity$ ―$ ―$ ―$ ―$ ―
Cash Flow
Free Cash Flow$ 3.55B$ 6.62B---
Operating Cash Flow$ 6.08B$ 15.08B$ 6.02B$ 5.54B-
Investing Cash Flow
Financing Cash Flow
Currency in USD

Beximco Pharmaceuticals Limited Sponsored GDR RegS Earnings and Revenue History

Beximco Pharmaceuticals Limited Sponsored GDR RegS Debt to Assets

Beximco Pharmaceuticals Limited Sponsored GDR RegS Cash Flow

Beximco Pharmaceuticals Limited Sponsored GDR RegS Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis